Association between mitogenicity and immunogenicity of 4-hydroxy-3,5- dinitrophenacetyl-lipopolysaccharide, a T-independent antigen by unknown
Brief Definitive Report 
ASSOCIATION  BETWEEN  MITOGENICITY AND 
IMMUNOGENICITY OF 4-HYDROXY-3,5-DINITROPHENACETYL- 
LIPOPOLYSACCHARIDE,  A  T-INDEPENDENT  ANTIGEN* 
BY EDVARD  SMITH, LENNART  HAMMARSTROM  AND ANTONIO COUTINHO 
(From the Division of  lmmunobiology , Karolinska Institutet,  Wallenberglaboratory , Lilla Frescati, 
104 05 Stockholm 50, Sweden, and the Basel Institute for Immunology, Grenzacherstrasse 487, CH- 
4058 Basel, Switzerland) 
Thymus-independent (TI)  induction of antibody production is the simplest 
model for the study of B-cell triggering mechanisms (1) and the direct B-cell 
responses to many bacterial products appear to be of major importance in the 
economy of the immune system (2). One common characteristic of TI antigens is 
their ability to induce polyclonal antibody synthesis in B lymphocytes when 
added in high concentrations (1) but specific antibody synthesis when given in 
10  -e or lower concentrations (1). Another common property, which is not shared 
by all TI antigens, is their structure of repeating antigenic determinants. These 
characteristics constitute the  basis  for two  current competing "one  signal" 
concepts of B-cell activation. Thus, it has been postulated that B-cell triggering 
is  the  result  of one specific signal  generated by the interaction of suitably 
presented antigenic determinants with the  surface Ig receptors,  or  alterna- 
tively, that  B  cells are activated by one nonspecific signal delivered by the 
nonspecific polyclonal B-cell activating (PBA)  properties of the  antigen  (for 
review see 3). The latter model ascribes to the surface Ig receptors on B cells a 
passive function of focusing nonspecific triggering signals onto the cell mem- 
brane. 
To  distinguish between these two alternatives,  we have  made use of the 
antibiotic polymyxin B (PB),  which is competent to inactivate the nonspecific 
activating properties of a well known TI antigen and a PBA, namely lipopoly- 
saccharide (LPS),  from gram-negative bacteria (4), 
Materials and Methods 
Mice.  B10.SM (H-2 b) and C57BL (H-2 ~) mice of both sexes, 6-8 wk of age from our own colony, 
were used in all the experiments. 
Culture Conditions.  The method for the study of polyclonal proliferative responses to LPS and 
LPS-PB conjugates, as well as for the induction of specific TI anti-4-hydroxy-3,5-dinitrophenacetyl 
(NNP) antibody responses by NNP-LPS,  has been described earlier (5, 6). 
LPS.  LPS  from Escherichia  coli  O55:B5  obtained  by  phenol-water  extraction  (7)  was  used 
throughout these experiments. The hapten NNP was conjugated to LPS as previously described 
(6), and the biological characterization of the conjugate used in the present experiments has been 
presented before (8). The final conjugation ratio was 10 -5 M NNP/mg LPS, and the amount of LPS 
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in the stock solution  was approximately 10 mg/ml. Serial fourfold dilutions  were prepared for 
testing and are recorded in the tables and figures as Log4  dilutions.  Thus, 5 Log~  dilution  = 1:1,024. 
Polymyxin B Sulphate.  PB  (batch  14124) was a  gift from 3 M Riker Laboratories, Great 
Britain. 
Detection of  Antibody-Producing Cells.  The number of antibody-producing  cells (plaque-form- 
ing cell, PFC) to the hapten NNP was determined by the use of a modification of the hemolytic 
plaque assay in agar (9) for detecting low-affinity (pelyclonal) or high-affinity (specific) antihap- 
ten PFC. 
Inhibition of Rosette-Forming Cells.  NNP-LPS was mixed with different  amounts of PB and 
allowed to interact for 15 min at room temperature. Anti-NNP spleen cells from hyperimmunized 
mice were  admixed and left for additional  15 rain  at room temperature.  Without subsequent 
washing NNP-coated SRBC were added and the suspensions centrifuged for 10 min at 4°C to allow 
formation of rosette-forming cell (RFC). Details of this method have been published elsewhere 
(10). 
Dialysates.  Different concentrations  of LPS and PB dissolved in balanced salt solution  (BSS) 
were mixed at room temperature and allowed to react for 30 min. The mixtures were thereafter 
transferred to dialysis bags (Union Carbide  Corp., New York) and extensively dialyzed against 
BSS to remove unreacted PB. 
Results 
PB Inhibits Mitogenicity of LPS.  LPS was pretreated with PB, followed by 
dialysis  to  remove  excess  PB.  The  treated  LPS  was  subsequently  added  to 
spleen cells. Results of such an experiment are shown in Fig.  1. As can be seen, 
untreated LPS dialyzed against BSS induced a proliferative response in spleen B 
cells exhibiting  a  typical dose response profile.  PB-treated  LPS preparations, 
however, were significantly less mitogenic. The degree of inhibition of mitogen- 
icity increased with the PB concentrations used for inactivation.  PB treatment 
of LPS  did  not  completely  abolish  mitogenicity,  and  the  preparations  were 
competent to induce a  proliferative response, but much higher LPS concentra- 
tions were required to achieve the same level of responses. 
PB  Inhibits  the  Capacity  of LPS  to  Induce  Polyclonal  Antibody  Synthe- 
sis.  Similar  experiments  were  performed  to  evaluate  the  capacity  of  PB- 
treated LPS to induce polyclonal antibody synthesis in resting B cells. This was 
done  by  determining  numbers  of high  rate  antibody  secreting  cells  (PFC) 
against  sheep red blood cells  (SRBC)  coupled with  a  high density  of haptenic 
determinants.  As  can  be  seen  in  Table  I,  PB-treated  LPS  was  significantly 
inhibited in the ability to induce polyclonal antibody synthesis. The inhibition 
was not  complete,  and  higher  concentrations  of PB-treated  LPS could induce 
polyclonal antibody synthesis. 
PB  Inhibits  the  Specific  TI Immune  Response  to  a  Hapten  LPS  Conju- 
gate.  Having established that PB is competent to inhibit the nonspecific B-cell- 
activating properties of LPS,  we investigated  its  ability to interfere  with the 
specific TI immune response to a  hapten-LPS conjugate.  If B-cell triggering in 
specific  responses  is  also  the  result  of nonspecific  signals  delivered  by  PBA 
properties  of LPS,  the  responses  should be expected to be inhibited.  Alterna- 
tively, if specific B  cells were triggered by one specific signal delivered by the 
"pattern  of antigen  presentation,"  no effect should  occur after PB  treatment. 
Since the amount of LPS in the conjugate concentrations,  which are required to 
induce optimal in vitro responses to the hapten, is extremely low (ranging from 
10 pg/ml to 10 ng/ml), low nontoxic concentrations of PB, directly added to the c~  c_J 
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FIG.  1.  Induction of DNA synthesis by LPS pretreated with 0 (A), 20 (-  El), or 200 ( ..... [3) 
~g/ml of PB. 
TABLZ I 
Inhibition of Polyclonal Response to LPS by Pretreatment with PB in 
Percent of Normal PFC Response 
LPS 
100 ~g/ml  10 ~.g/ml  1 ~g/ml  0.1 p.g/ml 
200 ~g/ml PB  2  28  44  45 
20 ~g/ml PB  0  19  28  31 
cultures,  should be sufficient to  inactivate  the  mitogen.  As shown in  Fig.  2, 
normal spleen cells given NNP-LPS mount a good high-avidity antihapten PFC 
response  in  vitro.  As  for  all  other  direct  B-cell responses,  the  dose-response 
profile is bell shaped,  superoptimal concentrations  of the antigen  resulting in 
paralysis of the hapten-specific cells. 
Addition of PB results in a shift of the whole dose-response curve to the right, 
indicating  that  a  loss  of immunogencity  took  place  in  the  presence  of the 
inhibitor.  The  enhanced  PFC  response  seen  with  high  amounts  of PB could 
reflect a  decreased toxicity of LPS.  Therefore  we conclude that  PB,  which is 
competent to inhibit the nonspecific B-cell-activating properties of LPS, is also 
competent to inhibit the specific antihapten response to a hapten-LPS conjugate, 
strongly suggesting that the nonspecific activating properties of the antigen are 
strictly required for the induction of the specific responses. 1524 
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FIG.  2.  Induction of specific anti-NNP  PFC with NNP-LPS  conjugates after addition of 0 
(A),  1  (D),  or 10 (I)  /~g/ml PB. 
PB  Does  Not  Show  Immunological  Cross-Reactivity  with  the  Hapten 
NNP.  To conclude that the PB-induced inhibition is nonspecific, it should be 
demonstrated that PB does not cross-react with the antigen. PB was incorpo- 
rated into the agar used for the assay of PFC with cells that had been activated 
by NNP-LPS in vitro. As can be seen in Table II, no inhibition was detected. 
Thus, we conclude, that the inhibition of the TI immune response to NNP-LPS 
by PB is not due to cross-reactivity of PB with the hapten NNP. 
PB  Does  Not Interfere  with  the  Expression  of NNP Determinants  on  the 
Immunogenic Conjugate.  It seems possible that PB could specifically inhibit 
the response to the conjugate by interacting with the conjugate in such a way 
that the  availability of the  haptenic groups  would be  changed.  To test this 
possibility, we used a rosette inhibition assay. This is a good test for functional 
availability of haptenic groups,  and the amount of inhibition depends on the 
amount of hapten in the particular conjugate that is to be studied. As can be 
seen in Fig. 3, the NNP-LPS conjugate was competent to inhibit hapten-specific 
RFC,  demonstrating that haptenic groups  were available for the  inhibition. 
Furthermore, the conjugate, pretreated with inhibitory concentrations of PB, 
was as inhibitory for RFC formation. Inhibition was specific since the SRBC- 
RFC response was unaffected by NNP-LPS conjugates. SMITH  ET  AL.  BRIEF  DEFINITIVE  REPORT 
TAm.,E II 
Effect of Incorporation of Free PB in the Anti-NNP PFC Assay 
PB  PFClculture induced by  Control  PFClculture 
NNP-LPS II Log, dilution 
Izg/ml 
0  520  20 
0.001  462  32 
0.01  444  18 
O. 1  556  25 
1  476  28 
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FIG.  3.  Rosette inhibition of  hyperimmune  anti-NNP spleen cells  with NNP-LPS  conju- 
gates with addition of  0 (A), 1 (- D), or 10 (  ....  [~) ~g/ml of  PB. 
Therefore,  we conclude that  PB does not interfere  with the binding  of the 
immunogenic  conjugate to the hapten-specific  cells.  Since RFC inhibition  de- 
pends on the valency of the conjugates (11),  as well as on the total amount of 
hapten in the reaction,  these results indicate that PB does not modify, in any 
detectable way, the "pattern of determinant presentation" to the specific cells. 
Discussion 
The present results demonstrate that the immunogenicity of a hapten conju- 
gate is inhibited by inhibiting the nonspecific B-cell activating properties of the 
carrier.  Therefore,  it has to be concluded that  B-cell activation in specific TI 
responses does not take place in the absence of a nonspecific (non-Ig-mediated) 
signal. The results indicate that antigen presentation as such (and therefore the 
interaction of antigen with Ig receptor) is not disturbed, since the binding of the 
conjugate to specific cells in the presence of the inhibiter was not affected. These 1526  SMITH  ET  AL.  BRIEF  DEFINITIVE  REPORT 
findings exclude the concept that B-cell triggering is the result of one specific (Ig 
mediated)  signal  and  strongly argue  for  a  strict  requirement for functional 
<<mitogenicity" or PBA activity of  the carrier in order to be immunogenic and TI. 
However, the results do not give information on whether or not an Ig-mediated 
signal also plays a  role in the inductive process, although recent experiments 
suggest that no signal is generated at the Ig-combining site. 
The present experiments should be compared with a recently published report 
(12) which used the same experimental design, but reached opposite conclusions. 
Thus,  Jacobs  and  Morrison  have  shown  that  PB  was  competent to  inhibit 
polyclonal (mitogenic) responses induced by LPS. This is in agreement with our 
findings. However, in their report,  PB was found to enhance, rather than to 
inhibit, the specific antihapten response to a hapten-LPS conjugate. This is in 
complete contrast to our results. It is unlikely that this phenomenon is specific, 
since we did not find any cross-reactivity between PB and NNP, the latter being 
highly cross-reactive  with  TNP.  There  may be  many explanations to  these 
discrepancies, although the most plausible explanation is the different culture 
systems used. 
PB might prove to be a useful tool for the future investigation of  the molecular 
basis of B-cell activation by LPS, and experiments in this direction are presently 
being carried out. 
Summary 
Polymyxin B,  which is  a  basic polypeptide produced by various strains of 
Bacillus Polymyxa, has previously been shown to prevent the lethal effect of 
LPS  and  to  neutralize  the  Schwartzmann reaction.  In  this  study  we  have 
investigated  the  interactions  between  polymyxin B  and  lipopolysaccharide 
(LPS) and hapten LPS conjugates. Polymyxin B was found to suppress mitogen- 
icity of LPS  and  also  to  inhibit immunogenicity of the  hapten  conjugate 4- 
hydroxy-3,5-dinitrophenacetyl (NNP)-LPS. Inhibition was not due to interfer- 
ence with the expression of NNP determinants nor to cross-reactivity between 
PB and the hapten. Since mitogenicity and immunogenicity  decreased in paral- 
lel, we conclude that B-cell activation in specific thymus independent responses 
does not take place in the absence of a nonspecific (non-Ig-mediated) signal. 
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